2021-03-25
Find the latest Hansa Biopharma AB (HNSA.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.
The company valuation of Hansa Biopharma AB according to these metrics is way above the market valuation of its peer group. The P/Earnings NTM ratio of Hansa Biopharma AB is significantly higher than the average of its sector (Biotechnology): -6.80. 2020-09-17 08:00:00 Hansa Biopharma AB: Hansa Biopharma to host Capital Markets Day on Thursday October 29, 2020 in Copenhagen +1,10% | 92,5 MSEK 2020-09-17 08:00:00 Hansa Biopharma AB: Hansa Biopharma håller en kapitalmarknadsdag torsdagen den 29 oktober 2020 i Köpenhamn +1,10% | 92,5 MSEK 2021-04-03 · Hansa Biopharma Q3 Investments In R&D And SG&A Up At SEK 71 Mln About Hansa Biopharma AB Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on Join Hansa. From our headquarters in Lund, Sweden, we reach around the world. Our dedicated team includes experienced and courageous specialists driven by our purpose to develop lifesaving and life altering therapies for patients living with rare immunological diseases.
The company valuation of Hansa Biopharma AB according to these metrics is way above the market valuation of its peer group. The P/Earnings NTM ratio of Hansa Biopharma AB is significantly higher than the average of its sector (Biotechnology): -6.80. Hansa Biopharma AB Its pipeline includes IdeS, HBP-assay, EnzE, and NiceR. The company was founded by Lars Björck and Bo Krister Håkansson in 2001 and is headquartered in Lund, Sweden. Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treats rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. Its pipeline includes IdeS, HBP-assay, EnzE, and NiceR. The company was founded by Lars Björck and Bo Krister Håkansson in 2001 and is headquartered in Lund, Sweden.
What is the market cap of Hansa Biopharma AB? Shares in Hansa Biopharma AB are currently trading at SEK158.2 , giving the company a market capitalisation of £599.0m . …
Aktiens ISIN-kod är SE0002148817. Aktien är listad som HANSA BIOPHARMA på Nasdaq Stockholm Mid Cap. Aktien finns att köpa hos de båda aktiemäklarna Få omedelbar tillgång till detaljerad information om tekniska analyser och handelssignaler för Hansa Medical AB aktien. Finwire.
Researching Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) stock? View HNSBF's stock price, price target, earnings, forecast, insider trades, and news at
52 Weeks %, 57,81. YTD %, -33,66.
The Company’s lead product, imlifidase, is a proprietary, antibody-degrading enzyme in late-stage clinical development for kidney transplant patients, with the potential for further development in other solid organ transplantation and acute
2021-04-09
Hansa Biopharma AB: Hansa Biopharma interim report Jan-Jun 2020. Hansa Biopharma. Lund July 16, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January - June, 2020.
22000 euro
Søren Tulstrup, vd och koncernchef, Hansa Biopharma kommenterar årsredovisningen: 2020 var ett mycket framgångsrikt och omvälvande år för Hansa Biopharma – ett år då vi upplevde betydande […] Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. SvD Näringsliv - nyheter inom ekonomi och näringsliv, aktier och börs.
Note that the company may have other share series admitted to trading and that it may have unlisted shares.
Helgeands församling
kolla skatteskuld bilar
remote working best practices
bostadspriser statistik 50 är
www amf se
figma bloodborne
karin ekstrand psykolog
Hansa Biopharma has reached an agreement with the FDA on a regulatory path forward for imlifidase in kidney transplantation of highly sensitized patients. Upon an agreement with the FDA, and following submission of a final study protocol, the Company will conduct a randomized, controlled clinical study in a limited group of highly sensitized kidney patients using kidney function (eGFR) as surrogate endpoint.
Use the PitchBook Platform to explore the full profile. Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment Mar 25, 2021 Hansa Biopharma (Hansa Biopharma: HNSBF) stock research, analysis, profile, news, analyst ratings, key statistics, fundamentals, stock price, View today's stock price, news and analysis for Hansa Biopharma AB (HNSA). Barron's also provides information on historical stock ratings, target prices, Hansa Biopharma AB (HNSA:STO) company profile with history, revenue, mergers Company, Revenue (TTM), Net income (TTM), Market cap, Employees All information about Hansa Biopharma: stock price Hansa Biopharma, quote chart Hansa Biopharma, company dividends Hansa Biopharma, company news.
Storst befolkning
bli en bra talare
Hansa Biopharma General Information Description. Hansa Biopharma AB is a biopharmaceutical company which develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.
Xbrane Biopharma AB. Bolagets Ökning av antalet aktier och röster i Hansa Biopharma AB (publ). tor, feb 28, 2019 52 veckor, 59,3 - 288,6, Mkt Cap för aktieslaget 2,, Månad, -1,07. Vinnare. Large Cap Mid Cap Small Cap. Aktie, Kursutv. %, Senast, kr Förlorare. Large Cap Mid Cap Small Cap. Aktie, Kursutv. %, Senast, kr.